Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma

被引:3
|
作者
Soetandyo, Noorwati [1 ]
Hanafi, Arif Riswahyudi [2 ]
Agustini, Sri [1 ]
Sinulingga, Dian Triana [3 ]
机构
[1] Dharmais Natl Canc Ctr Hosp, Dept Hematol & Med Oncol, Jakarta, Indonesia
[2] Dharmais Natl Canc Ctr Hosp, Dept Pulmonol, Jakarta, Indonesia
[3] Dharmais Natl Canc Ctr Hosp, Jakarta, Indonesia
关键词
chemotherapy; histology; lung cancer; prognosis; BODY-MASS INDEX; SURVIVAL; EFFICACY; MORTALITY; OUTCOMES; SMOKING;
D O I
10.13181/mji.oa.203787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In Indonesia, lung cancer is one of the most prevalent solid cancer with the highest mortality rate. However, studies to identify prognostic factors associated with mortality are lacking. Thus, this study was aimed to determine the association of histological subtypes and prognosis of advanced stage non-small-cell lung cancer (NSCLC) patients receiving chemotherapy. METHODS This study focused on a retrospective cohort consisting of 60 patients with advanced stage NSCLC and treated with chemotherapy. Patients with NSCLC stage IIIB or stage IV, age >= 18 years, and good performance status were recruited. The outcomes were one-year mortality and treatment response. Gender, age, body mass index, staging, and performance status were evaluated. Chi-square and Fisher's exact tests were used. RESULTS Two common histological subtypes, adenocarcinoma (68.3%) and squamous cell carcinoma (31.7%), were observed among all subjects. Four patients (6.7%) died during one-year observation period. Mortality rate was higher in squamous cell carcinoma (10.5%) patients than in adenocarcinoma (4.9%). Underweight patients had higher risk of death (relative risk [RR] = 1.09, 95% confidence interval [CI] = 1.00-1.19) and disease progression (RR = 1.30, 95% CI = 1.12-1.51). In adenocarcinoma, metastasis was a risk for progressive disease (RR = 1.35, 95% CI = 1.09-1.66). In squamous cell carcinoma, men had a lower risk of disease progression (RR = 0.11, 95% CI = 0.03-0.41). CONCLUSIONS Squamous cell carcinoma had comparable one-year mortality and disease progression rate with adenocarcinoma type in advanced stage NSCLC. However, underweight patients had a higher risk of mortality and disease progression.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [1] Treatment and prognosis of advanced stage non-small-cell lung cancer
    Ben Abdallah, F. Chermiti
    Ben Ali, G.
    Boudaya, M. Sadok
    Mlika, M.
    Chtourou, A.
    Taktak, S.
    Ben Kheder, A.
    REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (03) : 214 - 220
  • [2] Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China
    Chai, Qingqing
    Shen, Yunjie
    Du, Jiangyang
    Zhu, Jun
    Wu, Bin
    IMMUNOTHERAPY, 2020, 12 (04) : 245 - 254
  • [3] Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Palliative Chemotherapy
    Daroszewski, Cyryl
    Stasiewicz, Malgorzata
    Jazwinska-Tarnawska, Ewa
    Rachwalik, Anna
    Mura, Ewa
    Luboch-Kowal, Joanna
    Drys, Andrzej
    Bogucki, Zdzislaw A.
    Brzecka, Anna
    ADVANCES IN PULMONARY MEDICINE: RESEARCH AND INNOVATIONS, 2019, 1160 : 11 - 18
  • [4] PROGNOSTIC IMPACT OF CANCER CACHEXIA IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER RECEIVING CHEMOTHERAPY
    Kimura, Madoka
    Naito, Tateaki
    Wakuda, Kazushige
    Oyakawa, Takuya
    Hisamatsu, Yasushi
    Imai, Hisao
    Tokito, Takaaki
    Ono, Akira
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Shukuya, Takehito
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S490
  • [5] Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients
    Nasser, Fabio
    Souza Cruz, Marcelo Rocha
    Riera, Rachel
    JAMA ONCOLOGY, 2016, 2 (12) : 1645 - 1646
  • [6] Chemotherapy for elderly patients with advanced non-small-cell lung cancer
    Bunn, PA
    Lilenbaum, R
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) : 341 - 343
  • [7] Patients preferences in chemotherapy for advanced non-small-cell lung cancer
    Hirose, T
    Horichi, N
    Ohmori, T
    Kusumoto, S
    Sugiyama, T
    Shirai, T
    Ozawa, T
    Ohnishi, T
    Adachi, M
    INTERNAL MEDICINE, 2005, 44 (02) : 107 - 113
  • [8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02): : 123 - 135
  • [9] Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
    Ito, Yasuhiro
    Karayama, Masato
    Inui, Naoki
    Kuroishi, Shigeki
    Nakano, Hideki
    Nakamura, Yutaro
    Yokomura, Koshi
    Toyoshima, Mikio
    Shirai, Toshihiro
    Masuda, Masafumi
    Yamada, Takashi
    Yasuda, Kazumasa
    Hayakawa, Hiroshi
    Suda, Takafumi
    Chida, Kingo
    LUNG CANCER, 2014, 84 (03) : 259 - 264
  • [10] Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma
    Kuribayashi, Kozo
    Funaguchi, Norihiko
    Nakano, Takashi
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 528 - 534